AI drug development startup Pathos AI closes $237M investment

SiliconANGLE – AIMédia · il y a 3 heures

Pathos AI Inc. today announced that it has raised $237 million in funding at a $3 billion valuation. Pharmaceutical giant Bristol Myers Squibb Co. led the Series E round with participation from several unnamed returning backers. Pathos’ investor roster includes big names such as AstraZeneca plc, NEA and General Atlantic. Pathos is developing cancer drugs…

Extrait publié par SiliconANGLE – AI. Lisez l'article complet sur le site d'origine.

Discussion

Rejoignez la communauté pour réagir et poser vos questions.

Aucun message pour l'instant. Lancez la discussion !